Evidence map›Paper›PMID 37581164›Full record

ArticleInfection and drug resistance2023

Comparison of Epidemiological Characteristics Between ESBL and Non-ESBL Isolates of Clinically Isolated

Wei Zhang, Qing Wang, Liru Zhang, Jiangxiong Wu, Jinlu Liu, Cheng Lu, Xinsheng Wang, Zhihua Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Wei Zhang *Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, People's Republic of China.ORCID 0000-0002-0581-2812
Qing Wang *Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, People's Republic of China.
Liru Zhang *Clinical Laboratory, Zhangjiakou Wanquan District Hospital, Zhangjiakou, Hebei, People's Republic of China.
Jiangxiong WuInspection Center, Qujing No.1 People's Hospital, Affiliated Qujing Hospital of Kunming Medical University, Qujing, Yunnan, People's Republic of China.
Jinlu LiuMicrobiology Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
Cheng LuMicrobiology Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
Xinsheng WangCentral Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
Zhihua ZhangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
Hebei North University · CNKunming Medical University · CNState Administration of Traditional Chinese Medicine of the People's Republic of China · CNZhangjiakou Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This single-center study aims to investigate the epidemiological characteristics of clinically isolated Methods: In vitro drug sensitivity of Results: Over the study period, carbapenem resistance rates increased by more than 50% (2022 [1.34%] vs 2014 [0.8%]) and the annual number of isolates showed an upward trend (1264 in 2022 vs 501 in 2014). Drug resistance rates were the highest for penicillin (75-85%) and lowest for imipenem (1%). The resistance rate of strains isolated from male patients and sputum was found to be higher than that of female patients and urine, except for quinolones ( Conclusion: Carbapenems remain the optimal choice for treating extended spectrum beta-lactamase-producing

Indexed as

antibiotic resistancebacteriacarbapenemscephalosporinESBLquinolones

Identifiers

PMID37581164
PMCPMC10423568
OpenAlexW4385702892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.